TYRP1 and neoplasm: TA99 monotherapy is generally ineffective in established WT B16F10 tumors (Figure 2Aii and Figure S2A,B), which concurs with recent clinical trial results of anti-TYRP1 monotherapy against human melanoma that demonstrated safety but no anti-tumor efficacy [23].